{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-038095","form_type":"8-K","ticker":"BNGO","cik":"0001411690","company_name":"Bionano Genomics, Inc.","filed_at":"2023-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.838791+00:00","generated_at":"2026-06-12T05:50:35.093917+00:00","sec_items":["3.03","5.03","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bionano Genomics effects 1-for-10 reverse stock split, effective August 4, 2023","bullets":["Reverse stock split at ratio 1:10 effective 5:00 p.m. ET on August 4, 2023; trading on split-adjusted basis begins August 7, 2023.","No fractional shares issued; stockholders otherwise entitled to fractional share receive cash in lieu.","Proportionate adjustments to per-share exercise price and shares of stock options, RSUs, and warrants.","Certificate of Elimination filed for Series A Preferred Stock (no shares outstanding), removing designation from charter."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-038095","json":"https://secwatch.observer/filing/0001140361-23-038095.json","markdown":"https://secwatch.observer/filing/0001140361-23-038095.md","text":"https://secwatch.observer/filing/0001140361-23-038095.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411690/000114036123038095/0001140361-23-038095-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411690/000114036123038095/brhc20056936_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T05:50:35.093917+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2bece1ead52446c70dde7d18d215a65b7f0517bf","claim":"Bionano Genomics, Inc.: Amended certificate of incorporation to effect a 1-for-10 reverse stock split (effective 2023-08-04).","evidence_excerpt":"On August 4, 2023, Bionano Genomics, Inc. (the “ Company ”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation, as amended (the “ Restated Certificate ”), with the office of the Secretary of State of the State of Delaware to effect a reverse stock split at a ratio of 1:10 (the “ Charter Amendment ”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411690/000114036123038095/0001140361-23-038095-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-08-04"}],"fact_type":"governance_change"},{"claim_id":"d8d62850ea2ecc184beb27866769818ed661c977","claim":"Bionano Genomics, Inc.: Filed certificate of elimination to remove designation of Series A Preferred Stock and restore it to undesignated authorized preferred shares (effective 2023-08-04).","evidence_excerpt":"On August 4, 2023, prior to the Company’s filing of the Charter Amendment with the office of the Secretary of State of the State of Delaware, the Company filed a Certificate of Elimination (the “ Certificate of Elimination ”) with the office of the Secretary of State of the State of Delaware with respect to the Company’s Series A Preferred Stock, par value $0.0001 per share (the “ Series A Preferred Stock ”), following the automatic redemption of all outstanding shares of Series A Preferred Stock after the conclusion of the 2023 Annual Meeting.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411690/000114036123038095/0001140361-23-038095-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-08-04"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}